ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug

By Yahoo! Finance | Sep 11, 2024 at 02:49 PM EST

Piper Sandler downgraded Supernus Pharmaceuticals due to slower-than-expected growth in Qelbree prescriptions for ADHD. The company's focus on optimizing net economics may lead to more modest volume growth, with revised peak sales target at $400 million.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.